Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
10 07 2023
Historique:
received: 24 10 2022
accepted: 25 05 2023
medline: 11 7 2023
pubmed: 30 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

SARS-CoV-2 mRNA vaccination generates protective B cell responses targeting the SARS-CoV-2 spike glycoprotein. Whereas anti-spike memory B cell responses are long lasting, the anti-spike humoral antibody response progressively wanes, making booster vaccinations necessary for maintaining protective immunity. Here, we qualitatively investigated the plasmablast responses by measuring from single cells within hours of sampling the affinity of their secreted antibody for the SARS-CoV-2 spike receptor binding domain (RBD) in cohorts of BNT162b2-vaccinated naive and COVID-19-recovered individuals. Using a droplet microfluidic and imaging approach, we analyzed more than 4,000 single IgG-secreting cells, revealing high interindividual variability in affinity for RBD, with variations over 4 logs. High-affinity plasmablasts were induced by BNT162b2 vaccination against Hu-1 and Omicron RBD but disappeared quickly thereafter, whereas low-affinity plasmablasts represented more than 65% of the plasmablast response at all time points. Our droplet-based method thus proves efficient at fast and qualitative immune monitoring and should be helpful for optimization of vaccination protocols.

Identifiants

pubmed: 37252802
pii: 166602
doi: 10.1172/jci.insight.166602
pmc: PMC10371332
doi:
pii:

Substances chimiques

BNT162 Vaccine 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Biotechnol. 2017 Oct;35(10):977-982
pubmed: 28892076
Microbiol Spectr. 2022 Aug 31;10(4):e0092622
pubmed: 35700134
Immunity. 2022 Jun 14;55(6):1096-1104.e4
pubmed: 35483354
Cell Rep. 2020 Jan 28;30(4):997-1012.e6
pubmed: 31995768
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Clin Immunol. 2021 Jul;41(5):906-913
pubmed: 33725211
N Engl J Med. 2022 Aug 4;387(5):468-470
pubmed: 35857646
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18044-8
pubmed: 22025722
Sci Rep. 2021 Aug 24;11(1):17084
pubmed: 34429486
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
PLoS Pathog. 2021 Feb 11;17(2):e1009165
pubmed: 33571304
Nat Protoc. 2020 Sep;15(9):2920-2955
pubmed: 32788719
Nat Rev Immunol. 2022 Jan;22(1):7-18
pubmed: 34873279
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
J Exp Med. 2005 Mar 7;201(5):703-11
pubmed: 15738055
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Adv Biol (Weinh). 2023 Apr;7(4):e2200207
pubmed: 36517083
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Blood. 2007 Feb 15;109(4):1611-9
pubmed: 17032927
Cell Immunol. 1993 Dec;152(2):323-32
pubmed: 8258141
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Cell. 2021 Jul 22;184(15):3936-3948.e10
pubmed: 34192529
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35503254
Commun Biol. 2020 Oct 26;3(1):614
pubmed: 33106526
Nat Protoc. 2013 May;8(5):870-91
pubmed: 23558786
Science. 2003 Sep 5;301(5638):1374-7
pubmed: 12920303
Immunity. 2021 Dec 14;54(12):2893-2907.e5
pubmed: 34614412
Front Immunol. 2022 Jan 31;12:821729
pubmed: 35173713
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nature. 2022 May;605(7911):640-652
pubmed: 35361968
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Nature. 2022 Apr;604(7904):141-145
pubmed: 35168246
J Virol. 2022 Sep 14;96(17):e0058222
pubmed: 35976000
Cell Rep. 2021 Oct 12;37(2):109823
pubmed: 34610291
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2213056120
pubmed: 36595686
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027

Auteurs

Matteo Broketa (M)

Institut Pasteur, Université Paris Cité, Inserm UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.
Diaccurate SA, Paris, France.
Sorbonne Université, Collège Doctoral, F-75005 Paris, France.

Aurélien Sokal (A)

Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Université de Paris, Paris, France.

Michael Mor (M)

Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Pablo Canales-Herrerias (P)

Institut Pasteur, Université Paris Cité, Inserm UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.

Angga Perima (A)

Institut Pasteur, Université Paris Cité, Inserm UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.

Annalisa Meola (A)

Institut Pasteur, Université Paris Cité, CNRS UMR3569, Structural Virology, 75015 Paris, France.

Ignacio Fernández (I)

Institut Pasteur, Université Paris Cité, CNRS UMR3569, Structural Virology, 75015 Paris, France.

Bruno Iannascoli (B)

Institut Pasteur, Université Paris Cité, Inserm UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.

Guilhem Chenon (G)

Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.

Alexis Vandenberghe (A)

Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Université de Paris, Paris, France.
Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.
INSERM U955, Équipe 2. Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France.

Laetitia Languille (L)

Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Marc Michel (M)

Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Bertrand Godeau (B)

Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Sébastien Gallien (S)

Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Giovanna Melica (G)

Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Marija Backovic (M)

Institut Pasteur, Université Paris Cité, CNRS UMR3569, Structural Virology, 75015 Paris, France.

Felix A Rey (FA)

Institut Pasteur, Université Paris Cité, CNRS UMR3569, Structural Virology, 75015 Paris, France.

Jean Baudry (J)

Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.

Natalia T Freund (NT)

Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Matthieu Mahévas (M)

Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Université de Paris, Paris, France.
Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.
INSERM U955, Équipe 2. Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France.
Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Créteil, France.

Pierre Bruhns (P)

Institut Pasteur, Université Paris Cité, Inserm UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.
Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH